S-1: Plus Therapeutics Files S-1 for Up to $50 Million Equity Offering with Lincoln Park Capital Amidst Going Concern Warning

Plus Therapeutics, Inc. has filed an S-1 registration statement to register the resale of up to 17,000,000 shares of common stock to Lincoln Park Capital Fund, LLC, potentially raising up to $50 million in gross proceeds for working capital and general corporate purposes, while facing a 'going concern' qualification from its auditors.

Summary

• Plus Therapeutics, Inc. has filed a Form S-1 registration statement to register the resale of up to 17,000,000 shares of its common stock by Lincoln Park Capital Fund, LLC.
• The company will not receive any proceeds from the resale of shares by Lincoln Park, but may receive up to $50 million in aggregate gross proceeds from direct sales of common stock to Lincoln Park under a Purchase Agreement dated June 17, 2025.
• An Initial Commitment Fee of $500,000 is payable to Lincoln Park in cash, shares, or a combination, and an Additional Commitment Fee of $500,000 is payable upon the company receiving $25 million in gross proceeds from sales to Lincoln Park.
• Shares sold to Lincoln Park will be priced based on market conditions, with a floor price of $0.10 per share.
• As of June 16, 2025, the closing price of Plus Therapeutics' common stock (PSTV) on Nasdaq was $0.31 per share.
• Assuming a purchase price of $0.31 per share, the sale of all 17,000,000 registered shares would yield approximately $5.3 million in gross proceeds to the company, leaving $44.7 million of the $50 million commitment available.
• The offering is subject to a Nasdaq limit of 19.99% of outstanding shares (10,194,593 shares) unless stockholder approval is obtained.
• Lincoln Park's beneficial ownership is capped at 4.99% of the company's then outstanding common stock.
• The company's historical net tangible book value as of March 31, 2025, was approximately $(19.3) million, or $(1.44) per share, which is estimated to increase to $(0.57) per share after the assumed sale of 17,000,000 shares.
• The independent registered public accounting firm's report on the consolidated financial statements contains an explanatory paragraph regarding the company's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit 'going concern' warning from auditors, the substantial potential for dilution from the equity line of credit, and the company's ongoing need for significant capital raises at a low stock price, indicating a precarious financial position and high investment risk.

Positives

• Secures a potential source of up to $50 million in capital over a 36-month period, providing funding for working capital and general corporate purposes.
• The company retains sole discretion over the timing and amount of share sales to Lincoln Park, offering financial flexibility.
• Lincoln Park Capital is prohibited from engaging in short-selling or hedging of the company's common stock during the term of the Purchase Agreement, potentially reducing downward pressure from the investor.

Negatives

• The offering carries a high risk of substantial dilution to existing stockholders, as the company may issue a significant number of new shares.
• The sale of shares by Lincoln Park, or the anticipation of such sales, could cause the company's stock price to decline.
• The company's ability to access the full $50 million commitment is dependent on its stock price and market conditions, meaning the full amount may not be realized.
• The company's independent auditor has included an explanatory paragraph regarding its ability to continue as a going concern, indicating significant financial uncertainty.
• The company's net tangible book value is significantly negative, highlighting a challenging financial position.

Risks

• **Dilution Risk**: The sale or issuance of common stock to Lincoln Park may cause substantial dilution to existing stockholders, reducing the value of their investment.
• **Stock Price Volatility**: Sales of shares by Lincoln Park, or the anticipation of such sales, could lead to significant declines and high volatility in the company's common stock price.
• **Funding Uncertainty**: The company may not be able to access the full $50 million available under the Purchase Agreement, especially if the common stock price falls below the floor price or due to other limitations.
• **Need for Additional Capital**: Even with the Lincoln Park agreement, the company may require further financing to sustain operations, which could lead to additional dilutive equity or debt issuances.
• **Management Discretion**: Management has broad discretion over the use of net proceeds, and there is no guarantee that these funds will be invested successfully or yield a favorable return.
• **Future Equity Sales Difficulty**: The existence or anticipation of the arrangement with Lincoln Park could make it more difficult for the company to raise capital through other equity or equity-related securities in the future at desirable prices.
• **Nasdaq Listing Compliance**: The company is constrained by Nasdaq rules, limiting share issuance to 19.99% of outstanding shares without stockholder approval, which could restrict capital access.
• **Beneficial Ownership Limitation**: Lincoln Park is not obligated to purchase shares if it would result in their beneficial ownership exceeding 4.99% of the outstanding common stock.
• **Going Concern Uncertainty**: The auditor's report highlights substantial doubt about the company's ability to continue as a going concern, indicating significant financial challenges.
• **Anti-Takeover Provisions**: Provisions in the company's charter, bylaws, and Delaware law could delay or discourage changes in control, potentially depressing the market price of common stock.

Future Outlook

The company intends to use any proceeds from the Lincoln Park Purchase Agreement for working capital and general corporate purposes. It plans to re-introduce the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test to the U.S. market in the second half of 2025, following necessary certifications, state licensure, payor coverages, reimbursement codes, and financing. The company acknowledges that it may need additional capital beyond this offering to finance future production plans and working capital needs.

Management Comments

• Management has broad discretion as to the use of the net proceeds from the sale of shares of common stock to Lincoln Park, and the proceeds could be used for purposes other than those currently contemplated.
• The company's decision to enter into the Transaction Documents has been based solely on the independent evaluation by the Company and its representatives and advisors.

Industry Context

Plus Therapeutics operates in the high-risk, high-reward biopharmaceutical sector, specifically focusing on targeted radiotherapeutics for central nervous system (CNS) cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company's lead candidate, REYOBIQ, and its acquired CNSide Platform for cancer diagnostics position it in a specialized niche. Securing this equity line of credit is a common strategy for clinical-stage biotech companies to fund ongoing research, development, and operational expenses, especially given the long and costly development cycles for novel therapies. The 'going concern' warning, however, indicates that despite these funding efforts, the company faces significant financial challenges typical of early-stage biotechs without commercialized products.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face substantial potential dilution from the issuance of new shares under the Purchase Agreement and other recent/future capital raises. The value of their existing investment could be significantly reduced.
• **Employees**: The capital raised provides funding for ongoing operations and development activities, which could help secure employment and advance the company's strategic goals.
• **Creditors**: The additional capital infusion may improve the company's liquidity and ability to meet its financial obligations, although the 'going concern' warning suggests continued financial challenges.

Next Steps

• The company will file a Current Report on Form 8-K relating to the Lincoln Park transaction within the required timeframe.
• The company will file a new registration statement (S-1) covering the resale of Purchase Shares and Initial Commitment Shares within ten business days of the S-1 filing date.
• The company intends to seek stockholder approval to allow the issuance of common stock in excess of the 19.99% Nasdaq limit.
• The company plans to re-introduce the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test to the U.S. market in the second half of 2025 after completing necessary certifications, state licensure, payor coverages, reimbursement codes, and financing.
• The company may need to raise additional capital in the future to finance its production plans and working capital needs.

Key Dates

Recommendation

Keywords

SEC Filing, S-1, Equity Offering, Capital Raise, Dilution, Lincoln Park Capital, Common Stock, Biotechnology, Pharmaceutical, Radiotherapeutics, CNS Cancers, Glioblastoma, REYOBIQ, CNSide Platform, Nasdaq Capital Market, PSTV, Going Concern, Risk Factors